Medical Oncologist
Urothelial cancer
Targeted Therapy for — Bladder and Urothelial Cancer
Targeted therapy for bladder cancer is not the same for every patient. Which option your oncologist recommends depends on which mutations or proteins your tumour carries — found through biomarker testing on your biopsy tissue.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Testing decides eligibility — Targeted therapy only applies when specific mutations or proteins are found in your tumour tissue — your biopsy sample is usually enough.
- FGFR is the key mutation — FGFR2 and FGFR3 alterations are the most directly targetable changes in urothelial cancer, with a specifically approved inhibitor for tumours that carry them.
- ADCs work differently — Antibody-drug conjugates reach bladder cancer cells through NECTIN-4 and Trop-2 — proteins most urothelial tumours carry, regardless of FGFR status.
- A negative result still has a path — Not having an FGFR alteration does not mean no options. It means a different treatment is the better fit for your tumour.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Targeted therapy for bladder cancer works when specific mutations are found in your tumour tissue. FGFR2 and FGFR3 alterations are the most clinically actionable targets. Other markers — including NECTIN-4, Trop-2, and HER2 — guide antibody-drug conjugate treatments. Biomarker testing on your biopsy sample decides which, if any, apply to you.
Which mutations and proteins are tested in bladder cancer?
- FGFR2 / FGFR3 alteration
- A mutation or fusion in a gene that drives abnormal cell growth. Found in a meaningful proportion of urothelial cancers. An FGFR inhibitor has regulatory approval specifically for tumours that carry this change.
- HER2 (ERBB2)
- A growth protein that is overproduced in some bladder tumours. HER2 status is checked because certain treatments are designed to target it, particularly in combination regimens.
- NECTIN-4
- A protein found on the surface of most urothelial cancer cells. An antibody-drug conjugate uses it as a docking point to deliver chemotherapy directly inside cancer cells.
- Trop-2
- Another surface protein targeted by a different antibody-drug conjugate. Trop-2 expression is checked in the same panel and guides a separate treatment option.
- PD-L1
- A protein that helps tumours hide from the immune system. Tested alongside targeted therapy markers because it guides immunotherapy decisions — a related but distinct treatment choice.
- MSI / TMB
- Microsatellite instability and tumour mutational burden measure how much the tumour's DNA has changed. High levels may predict a better response to immunotherapy, regardless of cancer type.
How does your oncologist test for these mutations?
Testing is done on the tissue sample already taken during your diagnostic biopsy. You do not usually need a separate procedure.
The laboratory uses next-generation sequencing to scan your tumour DNA. One panel covers FGFR2/3, HER2, PD-L1, MSI, TMB, and other markers at the same time.
Results usually take one to two weeks. If the original sample is too small or degraded, a repeat biopsy or a liquid biopsy — testing DNA from the tumour that circulates in the blood — may be discussed with you.
What does each positive result open up?
An FGFR2 or FGFR3 alteration is the most directly actionable finding. NCCN and ESMO guidelines recommend an FGFR inhibitor for urothelial cancer with this change, typically after platinum-based chemotherapy.
NECTIN-4 and Trop-2 are targeted by antibody-drug conjugates — treatments that carry chemotherapy directly to cancer cells using a targeting protein. These do not require an FGFR result to be positive.
HER2 overexpression may open access to HER2-directed treatments, which are used in some combination regimens. Your oncologist will explain whether this applies to your stage and treatment history.
A positive PD-L1, MSI, or TMB result guides immunotherapy rather than targeted therapy. Both may be relevant for your care, sometimes in sequence.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What happens between your biopsy and starting treatment?
Tissue sample is confirmed
Your oncologist checks whether the biopsy tissue is adequate for molecular testing. Most diagnostic samples are sufficient.
Biomarker panel is sent to the laboratory
Next-generation sequencing is requested on your tumour tissue. This tests for FGFR, HER2, PD-L1, MSI, TMB, and other relevant markers in one process.
Results come back in one to two weeks
Your oncologist reviews the full panel. Each result narrows the treatment options toward what the evidence supports for your specific tumour.
Treatment decision is made together
Your oncologist recommends a treatment based on your results, your stage, and your general fitness. This is the appointment to ask what the recommended option is intended to achieve and what the side effects are.
Treatment starts as day care
Targeted therapy and antibody-drug conjugates for urothelial cancer are given intravenously in a day-care setting at CION. You do not usually need to stay overnight.
What do you need to know before your first targeted therapy appointment?
What if my FGFR result is negative?
A negative FGFR result means the FGFR inhibitor is not the right choice for your tumour — it does not mean you are out of options. Antibody-drug conjugates targeting NECTIN-4 and Trop-2 do not require an FGFR alteration and appear in NCCN-recommended pathways for urothelial cancer regardless of FGFR status. Your oncologist will review your full biomarker panel and previous treatment history before recommending what comes next.
Is targeted therapy only for advanced bladder cancer?
Most biomarker-guided targeted drugs for urothelial cancer are approved for the locally advanced or metastatic setting, typically after platinum-based chemotherapy. Earlier-stage bladder cancer is usually managed with surgery, radiation, or chemotherapy first. If your disease changes stage or recurs, the question of targeted therapy may become relevant again. Your oncologist will tell you which options apply at your current stage.
What are the side effects of FGFR inhibitors?
FGFR inhibitors have a different side effect profile from standard chemotherapy. Common effects include changes to the nails, skin, and mouth, along with elevated phosphate levels in the blood. Eye-related changes — including dry eyes and changes to the retina — are monitored with regular ophthalmology appointments scheduled before and during treatment. Tell your team immediately if your vision changes at any point, rather than waiting for your next scheduled visit.
How are antibody-drug conjugates different from standard chemotherapy?
An antibody-drug conjugate, or ADC, uses a targeting molecule to deliver chemotherapy directly to cancer cells that carry a specific surface protein. In urothelial cancer, those proteins are NECTIN-4 and Trop-2. Because the drug is guided to the cancer cell, some side effects differ from standard intravenous chemotherapy — but ADCs still carry real risks, including nerve effects and skin reactions, and your team will explain what to watch for before you start.
Will I need a repeat biopsy for biomarker testing?
Usually not. Testing is done on tissue from your original biopsy, which is preserved and stored in the pathology laboratory. A repeat procedure is only needed if the sample is too small, degraded, or was taken too long ago to be reliable. In that case, a new biopsy or a liquid biopsy — a blood test that detects tumour DNA circulating in the bloodstream — may be discussed. Ask your oncologist what sample was sent and when the results are expected.
Did you know?
Urothelial cancer is one of a small group of solid tumours where a single gene alteration — FGFR2 or FGFR3 — has led to a specifically approved targeted drug.
This makes comprehensive biomarker testing important from the start: a positive result you did not know you had can change the treatment pathway available to you.
Source: NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What is the most important mutation to test for in bladder cancer?
FGFR2 and FGFR3 alterations are currently the most directly actionable mutations in urothelial cancer. A targeted drug — an FGFR inhibitor — has regulatory approval specifically for tumours that carry these changes. Other markers, including HER2, NECTIN-4, Trop-2, PD-L1, and MSI, are also tested from the same tissue sample because separate treatments depend on each result. Your oncologist will explain which findings from your panel are relevant to your current treatment decision.
Is targeted therapy the same as immunotherapy for bladder cancer?
No — they are different treatments, though both may be relevant for your care. Targeted therapy blocks specific proteins or gene pathways that drive your tumour. Immunotherapy helps your immune system recognise and attack cancer cells. Bladder cancer is one of the few cancer types where both are used, sometimes in sequence and sometimes in combination. Your biomarker results will tell your oncologist which applies to you and in what order.
Can I have targeted therapy if I have already had chemotherapy?
Yes — in urothelial cancer, most targeted drugs and antibody-drug conjugates are recommended after platinum-based chemotherapy rather than as the first treatment. NCCN and ESMO guidelines position several of these options as second-line or later choices. Your oncologist will decide the sequence based on your biomarker results, your previous treatment response, and how you are doing overall. Being told targeted therapy comes later is not a deferral — it is the evidence-based sequence.
Will I need a new biopsy for biomarker testing?
Usually not. Testing is done on tissue from your original biopsy, stored in the pathology laboratory. If that sample is too small or degraded, a repeat biopsy or a liquid biopsy may be discussed. A liquid biopsy analyses tumour DNA found in a blood sample and can provide results when tissue is unavailable. Ask your team specifically whether a new sample is needed so you are not waiting on a result that requires a procedure you have not yet had.
Is targeted therapy for bladder cancer available in India?
Some targeted drugs for urothelial cancer have CDSCO approval in India, and others are accessible through approved access programmes. Availability changes as new approvals come through, so ask your oncologist which options are currently accessible for you and what the cost is likely to be. CION's oncology teams are familiar with the current Indian approval status for these medicines and can advise on practical access for your specific treatment.
What does it mean if there are no targetable mutations in my tumour?
It means the treatments that depend on those mutations are not the right fit — it does not mean you are out of options. Antibody-drug conjugates targeting NECTIN-4 and Trop-2 do not require a positive FGFR result. Immunotherapy may be appropriate depending on your PD-L1 and MSI results. Your oncologist will review the full panel together and recommend the best-supported treatment for your specific tumour, even when the most targeted options are not available.